3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Terminated
2
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Expanded_access
1
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
2
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Carboplatin
1145
Cisplatin
874
Pemetrexed
832
pembrolizumab
604
Paclitaxel
597
Docetaxel
535
Gemcitabine
424
Radiotherapy
374
Erlotinib Hydrochloride
367
Nivolumab
322
Bevacizumab
322
Etoposide
294
durvalumab
254
Drug Therapy
233
osimertinib
217
atezolizumab
207
Radiosurgery
188
Gefitinib
177
Vinorelbine
145
130-nm albumin-bound paclitaxel
123
Magnetic Resonance Spectroscopy
120
Ipilimumab
118
Cetuximab
113
anlotinib
104
tislelizumab
103
Topotecan
101
Cyclophosphamide
101
Taxes
99
Irinotecan
95
Albumin-Bound Paclitaxel
92
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
AM0010
×
Thoracic
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled
NCT03382899
2021-01-20
Cypress 1
Eli Lilly and Company
Phase 2
Terminated
101 enrolled
15 charts
NCT03382912
2020-09-11
Cypress 2
Eli Lilly and Company
Phase 2
Terminated
52 enrolled
15 charts